Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

n/a
Abstract Title:

Urinary melatonin in relation to postmenopausal breast cancer risk according to melatonin 1 receptor status.

Abstract Source:

Cancer Epidemiol Biomarkers Prev. 2016 Nov 9. Epub 2016 Nov 9. PMID: 28151704

Abstract Author(s):

Elizabeth E Devore, Erica T Warner, Heather Eliassen, Susan B Brown, Andrew H Beck, Susan Hankinson, Eva Schernhammer

Article Affiliation:

Elizabeth E Devore

Abstract:

BACKGROUND: Urinary melatonin levels have been associated with a reduced risk of breast cancer in postmenopausal women, but this association might vary according to tumor melatonin 1 receptor (MT1R) expression.

METHODS: We conducted a nested case-control study among 1,354 postmenopausal women in the Nurses' Health Study, who were cancer free when they provided first-morning spot urine samples in 2000-2002; urine samples were assayed for 6-sulfatoxymelatonin (aMT6s, a major metabolite of melatonin). Five-hundred fifty-five of these women developed breast cancer before May 31, 2012, and were matched to 799 control subjects. In a subset of cases, immunohistochemistry was used to determine MT1R status of tumor tissue. We used multivariable-adjusted conditional logistic regression to estimate the relative risk (RR) of breast cancer (with 95% confidence intervals [CI]) across quartiles of creatinine-standardized urinary aMT6s level, including by MT1R subtype.

RESULTS: Higher urinary melatonin levels were suggestively associated with a lower overall risk of breast cancer (multivariable-adjusted RR=0.78, 95% CI=0.61-0.99, comparing quartile 4 vs. quartile 1; p-trend=0.08); this association was similar for invasive vs. in situ tumors (p-heterogeneity=0.12). There was no evidence that associations differed according to MT1R status of the tumor (e.g., p-heterogeneity for overall breast cancer=0.88).

CONCLUSION: Higher urinary melatonin levels were associated with reduced breast cancer risk in this cohort of postmenopausal women, and the association was not modified by MT1R subtype.

IMPACT: Urinary melatonin levels appear to predict the risk of breast cancer in postmenopausal women. However, future research should evaluate these associations with longer-term follow-up and among premenopausal women.

Study Type : Human Study

Print Options


Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2019 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.